^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

NZV930

i
Other names: NZV930, SRF373
Associations
Trials
Company:
Coherus Biosci
Drug class:
CD73 inhibitor
Associations
Trials
1year
KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors (clinicaltrials.gov)
P1, N=77, Terminated, Novartis Pharmaceuticals | Active, not recruiting --> Terminated; Business reasons
Trial termination • Combination therapy • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
spartalizumab (PDR001) • KAZ954 • NZV930 • taminadenant (NIR178)
1year
KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors (clinicaltrials.gov)
P1, N=77, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting | N=145 --> 77
Enrollment closed • Enrollment change • Combination therapy • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
spartalizumab (PDR001) • KAZ954 • NZV930 • taminadenant (NIR178)
over1year
KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors (clinicaltrials.gov)
P1, N=145, Recruiting, Novartis Pharmaceuticals | Trial completion date: Feb 2025 --> Sep 2023 | Trial primary completion date: Feb 2025 --> Sep 2023
Trial completion date • Trial primary completion date • Combination therapy • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
spartalizumab (PDR001) • KAZ954 • NZV930 • taminadenant (NIR178)
over1year
KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors (clinicaltrials.gov)
P1, N=145, Recruiting, Novartis Pharmaceuticals | Trial completion date: Aug 2024 --> Feb 2025 | Trial primary completion date: Aug 2024 --> Feb 2025
Trial completion date • Trial primary completion date • Combination therapy • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
spartalizumab (PDR001) • KAZ954 • NZV930 • taminadenant (NIR178)